Bimiralisib
- Generic Name
- Bimiralisib
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20F3N7O2
- CAS Number
- 1225037-39-7
- Unique Ingredient Identifier
- 6Z3QHB00LB
- Background
Bimiralisib is under investigation in clinical trial NCT02723877 (PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)).
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- TORQUR
- Target Recruit Count
- 40
- Registration Number
- NCT06319794
- Locations
- 🇨🇭
University Hospital Basel / Department of Dermatology, Basel, Switzerland
🇨🇭CHUV centre hospitalier universitaire vaudois / Department of Dermatology and Venereology, Lausanne, Switzerland
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT03740100
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 9
- Registration Number
- NCT03127020
- Locations
- 🇩🇪
Medizinische Klinik und Poliklinik III, Munich, Bavaria, Germany
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- PIQUR Therapeutics AG
- Registration Number
- NCT03120000
- Locations
- 🇫🇷
Hématologie, Départment d'ongolgie médicale, Saint-Herblain, France
🇫🇷Aix-Marseilles Université, Marseille, France
🇫🇷Service de Neurology CHRU de Nancy, Nancy, France
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 10
- Registration Number
- NCT02850744
- Locations
- 🇨🇭
University Hospital Zurich, Neurology, Zurich, Switzerland
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 41
- Registration Number
- NCT02723877
- Locations
- 🇬🇧
Churchill hospital, Oxford, United Kingdom
🇪🇸Insitut Català d´Oncologia, Barcelona, Spain
🇬🇧Barts Cancer Institute, London, United Kingdom
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT02669511
Study of Oral PQR309 in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 70
- Registration Number
- NCT02483858
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 53
- Registration Number
- NCT02249429
- Locations
- 🇧🇦
University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina
🇬🇧Royal Marsden NHS Foundation Trust, London, United Kingdom
🇬🇧University College Hospital London, London, United Kingdom
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 28
- Registration Number
- NCT01940133
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.